PMID- 17284650
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20070207
IS  - 1066-5099 (Print)
IS  - 1066-5099 (Linking)
VI  - 25
IP  - 2
DP  - 2007 Feb
TI  - Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte 
      infusion suppresses growth of colon cancer cells implanted in skin and liver of 
      rats.
PG  - 385-91
AB  - We have recently found that allogeneic intrabone marrow-bone marrow 
      transplantation (IBM-BMT) + donor lymphocyte infusion (DLI) using CD4(+) 
      cell-depleted spleen cells (CD4(-) cells) can prevent graft-versus-host disease 
      (GvHD) but suppress tumor growth (Meth A: fibrosarcoma) in mice. In the present 
      study, we show that allogeneic IBM-BMT + DLI using CD4(-) cells also has 
      suppressive effects on the growth of colon cancer cells implanted not only in the 
      skin but also in the liver of rats. First, we examined the effects of allogeneic 
      IBM-BMT + DLI on the subcutaneously inoculated ACL-15 (rat colon cancer cell 
      line). Lethally irradiated Fischer rats (F344 rats) were transplanted with 
      T-cell-depleted bone marrow cells (BMCs) from Brown Norway (BN) rats. 
      Simultaneously, DLI was performed using whole spleen cells (whole cells), CD4(+) 
      cell-depleted spleen cells (CD4(-) cells) or CD8(+) cell-depleted spleen cells 
      (CD8(-) cells) of BN rats. Although allogeneic IBM-BMT + DLI suppressed tumor 
      growth, a considerable number of rats treated with allogeneic IBM-BMT + DLI using 
      whole cells or CD8(-) cells died due to GvHD. In contrast, allogeneic IBM-BMT + 
      DLI using CD4(-) cells also suppressed tumor growth, but there was no GvHD. Based 
      on these findings, we next examined the effects of allogeneic IBM-BMT + DLI using 
      CD4(-) cells on the cancer cells implanted in the liver. Allogeneic IBM-BMT + DLI 
      using CD4(-) cells via the portal vein significantly prolonged the survival. 
      These results suggest that allogeneic IBM-BMT + DLI using CD4(-) cells could 
      become a new strategy for the treatment of solid tumors.
FAU - Koike, Yasushi
AU  - Koike Y
AD  - First Department of Pathology, Kansai Medical University, 10-15 Moriguchi, Osaka, 
      Japan.
FAU - Adachi, Yasushi
AU  - Adachi Y
FAU - Suzuki, Yasuhiro
AU  - Suzuki Y
FAU - Iwasaki, Masayoshi
AU  - Iwasaki M
FAU - Koike-Kiriyama, Naoko
AU  - Koike-Kiriyama N
FAU - Minamino, Keizo
AU  - Minamino K
FAU - Nakano, Keiji
AU  - Nakano K
FAU - Mukaide, Hiromi
AU  - Mukaide H
FAU - Shigematsu, Akio
AU  - Shigematsu A
FAU - Kiyozuka, Yasuhiko
AU  - Kiyozuka Y
FAU - Tubura, Airo
AU  - Tubura A
FAU - Kamiyama, Yasuo
AU  - Kamiyama Y
FAU - Ikehara, Susumu
AU  - Ikehara S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
SB  - IM
MH  - Animals
MH  - *Bone Marrow Transplantation
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cell Proliferation
MH  - Colonic Neoplasms/*pathology
MH  - Killer Cells, Natural/immunology
MH  - Liver/*pathology
MH  - *Lymphocyte Transfusion
MH  - Rats
MH  - Rats, Inbred BN
MH  - Rats, Inbred F344
MH  - Skin/*pathology
MH  - Spleen/cytology/immunology
MH  - Survival Rate
MH  - Transplantation, Homologous
MH  - *Xenograft Model Antitumor Assays
EDAT- 2007/02/08 09:00
MHDA- 2007/03/16 09:00
CRDT- 2007/02/08 09:00
PHST- 2007/02/08 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2007/02/08 09:00 [entrez]
AID - 25/2/385 [pii]
AID - 10.1634/stemcells.2006-0227 [doi]
PST - ppublish
SO  - Stem Cells. 2007 Feb;25(2):385-91. doi: 10.1634/stemcells.2006-0227.